ID

13776

Description

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations; ODM derived from: https://clinicaltrials.gov/show/NCT01372384

Link

https://clinicaltrials.gov/show/NCT01372384

Keywords

  1. 3/6/16 3/6/16 -
Uploaded on

March 6, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT01372384

Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT01372384

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients, >/= 18 years of age
Description

age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
locally advanced (stage iiib), metastatic (stage iv) or recurrent non-small cell lung cancer with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (egfr)
Description

non-small cell lung cancer; Tyrosine kinase mutation; epidermal growth factor receptor

Data type

boolean

Alias
UMLS CUI [1]
C0007131
UMLS CUI [2]
C3267004
UMLS CUI [3]
C0034802
at least one measurable lesion according to recist criteria
Description

lesion

Data type

boolean

Alias
UMLS CUI [1]
C0221198
european cooperative oncology group (ecog) performance status 0-2
Description

ecog

Data type

boolean

Alias
UMLS CUI [1]
C1520224
adequate hematological, liver and renal function
Description

liver function; renal function; Hematologic function

Data type

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0221130
patients with stable cerebral metastases who have received surgical or radiotherapy will be eligible
Description

Cerebral metastasis; radiotherapy; surgery

Data type

boolean

Alias
UMLS CUI [1]
C0555278
UMLS CUI [2]
C1522449
UMLS CUI [3]
C0543467
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous chemotherapy or therapy against egfr for metastatic disease (neoadjuvant or adjuvant therapy after radical surgery is allowed if finalized >/= 6 months before entering the study)
Description

chemotherapy; therapy egfr; Neoadjuvant Therapy; adjuvant therapy; surgery

Data type

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0034802
UMLS CUI [3]
C0600558
UMLS CUI [4]
C0677850
UMLS CUI [5]
C0543467
history of another neoplasm except for carcinoma in situ of the cervix, adequately treated basal cell skin carcinoma, radically treated prostate carcinoma with good prognosis (gleason </= 6), or another curatively treated neoplasm without evidence of disease in the last 5 years
Description

cervix carcinoma in situ; basal cell skin carcinoma; prostate carcinoma; good prognosis

Data type

boolean

Alias
UMLS CUI [1]
C0851140
UMLS CUI [2]
C0007117
UMLS CUI [3]
C0600139
UMLS CUI [4]
C0278250
symptomatic cerebral metastases
Description

cerebral metastasis

Data type

boolean

Alias
UMLS CUI [1]
C0555278
any significant ophthalmologic abnormality
Description

Eye Abnormalities

Data type

boolean

Alias
UMLS CUI [1]
C0015393
use of coumarins
Description

Coumarins

Data type

boolean

Alias
UMLS CUI [1]
C0010207
pregnant or breast-feeding women
Description

pregnancy; lactating

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
pre-existing parenchymal lung disease such as pulmonary fibrosis, lymphangiosis and carcinomatosis (if this is the only presence of the disease)
Description

pulmonary fibrosis; Lymphangiosis carcinomatosa

Data type

boolean

Alias
UMLS CUI [1]
C0034069
UMLS CUI [2]
C0948588

Similar models

Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT01372384

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
age
Item
adult patients, >/= 18 years of age
boolean
C0001779 (UMLS CUI [1])
non-small cell lung cancer; Tyrosine kinase mutation; epidermal growth factor receptor
Item
locally advanced (stage iiib), metastatic (stage iv) or recurrent non-small cell lung cancer with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (egfr)
boolean
C0007131 (UMLS CUI [1])
C3267004 (UMLS CUI [2])
C0034802 (UMLS CUI [3])
lesion
Item
at least one measurable lesion according to recist criteria
boolean
C0221198 (UMLS CUI [1])
ecog
Item
european cooperative oncology group (ecog) performance status 0-2
boolean
C1520224 (UMLS CUI [1])
liver function; renal function; Hematologic function
Item
adequate hematological, liver and renal function
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0221130 (UMLS CUI [3])
Cerebral metastasis; radiotherapy; surgery
Item
patients with stable cerebral metastases who have received surgical or radiotherapy will be eligible
boolean
C0555278 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0543467 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
chemotherapy; therapy egfr; Neoadjuvant Therapy; adjuvant therapy; surgery
Item
previous chemotherapy or therapy against egfr for metastatic disease (neoadjuvant or adjuvant therapy after radical surgery is allowed if finalized >/= 6 months before entering the study)
boolean
C0392920 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C0034802 (UMLS CUI [2,2])
C0600558 (UMLS CUI [3])
C0677850 (UMLS CUI [4])
C0543467 (UMLS CUI [5])
cervix carcinoma in situ; basal cell skin carcinoma; prostate carcinoma; good prognosis
Item
history of another neoplasm except for carcinoma in situ of the cervix, adequately treated basal cell skin carcinoma, radically treated prostate carcinoma with good prognosis (gleason </= 6), or another curatively treated neoplasm without evidence of disease in the last 5 years
boolean
C0851140 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0600139 (UMLS CUI [3])
C0278250 (UMLS CUI [4])
cerebral metastasis
Item
symptomatic cerebral metastases
boolean
C0555278 (UMLS CUI [1])
Eye Abnormalities
Item
any significant ophthalmologic abnormality
boolean
C0015393 (UMLS CUI [1])
Coumarins
Item
use of coumarins
boolean
C0010207 (UMLS CUI [1])
pregnancy; lactating
Item
pregnant or breast-feeding women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
pulmonary fibrosis; Lymphangiosis carcinomatosa
Item
pre-existing parenchymal lung disease such as pulmonary fibrosis, lymphangiosis and carcinomatosis (if this is the only presence of the disease)
boolean
C0034069 (UMLS CUI [1])
C0948588 (UMLS CUI [2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial